In this video, Professor Dame Lesley Fallowfield explains why oncologists need to be aware of their own tolerance of uncertainty before discussing possible treatment risks and outcomes with patients.
Oncology nursing leader Deborah Boyle highlights some essential tips to address common issues in bedside care, staff communication, and on-the-job distress.
These are the first data to highlight the prognostic value of MGMT methylation beyond the IDH1/2 mutation status test currently used to help predict glioma patient survival outcomes.
An Australian team is studying a DNA-based vaccine that the lead investigator feels could be “transformative” in the care of advanced colorectal cancer.
DNA and RNA sequencing results suggest prostate cancer treatment “involving inhibition of CDK12 and immune checkpoint blockade,” a U Michigan team said.
This study is the first to show significantly improved OS from single-agent treatment in this particularly difficult to treat population.
The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma.
Preoperative pain, prothrombin time activity (PTA), albumin, urine protein, and postoperative chemotherapy appeared to be associated with prognosis.
Many MM patients experience a diagnostic interval longer than 3 months until diagnosis is confirmed, and several factors may account for this.
De-escalated treatment may be possible in patients with advanced HL who reach a metabolic response after only 2 cycles of escalated BEACOPP.